Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.50), $0.43 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $500.92 million versus the consensus estimate of $532.36 million.

The company reiterated 2024 financial guidance, including combined Net Product revenues of $1,575 million to $1,650 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.